The forum will feature 20-minute presentations (including Q&A) from a curated selection of exciting start-up companies, all carefully selected through our screening processes. You will also see updated presentations from past presenting companies.
TBD
Compact Medical received FDA clearance for their product, the ButterflyBVM™ in April 2025. They have secured pre-orders for over 2,300 units and are shipping the first orders to customers in July. They are looking for a partner to scale a nationwide launch of their life saving device.
Rising Wines Collective is scaling small-production wine sales through a DTC marketplace, offering curated clubs and direct access to craft winemakers. We’re building a suite of data-driven engagement tools—including an AI Wine Stylist app and custom-fit club—reimagining wine discovery with unmatched personalization and a modern approach traditional retailers can’t replicate.
Imagine a world without diabetes. Paulex Bio stands on the threshold of what could be a transformative breakthrough for Type 1 and Type 2 diabetes: an oral medicine designed to stimulate the regeneration of human beta cells to restore natural insulin production and potentially offer insulin independence to patients across the diabetes spectrum.
BleedIO builds secure, scalable Bluetooth Low Energy (BLE) mesh networks that provide real-time tracking, monitoring, and environmental sensing—without relying on Wi-Fi, GPS, or the cloud. Unlike traditional systems, our technology operates entirely at the edge using a decentralized mesh infrastructure. That means no single point of failure, no cloud latency, and no expensive infrastructure upgrades.
Eyetronic’s therapy has proven to halt vision loss (63%) and restore vision (59%). Eyetronic is approved in Europe with more than 1,000 patients treated in 10,000 sessions without a serious adverse event. Their revenue is generated through electronic codes (SaaS). Two clinical trials have started (Stanford, San Francisco) July 2025. Eyetronic’s goal is a US launch in 2028.